FDA 483 - Hina Budhwani - October 24, 2025

An FDA inspection of Hina S. Budhwani, MD, Clinical Investigator in Houston, TX, revealed one observation related to the conduct of an investigation. The firm failed to adhere to the investigational plan by not maintaining the required waiting period between doses for subjects in a clinical protocol. This indicates a deviation from established study procedures.